SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma’s arm gets nod to expand mammalian cell culture manufacturing facility

02 Sep 2022 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- CuraTeO Biologics (CuraTeQ) has received approval to expand its operations by establishing another mammalian cell culture manufacturing facility of higher capacity to cater to the future requirements. The capital expenditure for ramping up capacities is estimated to be around Rs 300 crore. Subject to regulatory approvals and other factors, the facility is likely to be fully operational by FY 2026.

CuraTeQ also received approval to enter into contract manufacturing operations (ICCMO) for biologicals for effective utilization of capacities and augmenting the business prospects in this area as the global biologics contract manufacturing demand is growing at 8 to 10% rate. CuraTeQ will actively seek customers in CMO area.

Also, Aurobindo Pharma’s wholly owned subsidiary -- Auro Vaccines (Auro), which is engaged in business of developing and manufacturing vaccines biologicals has decided to explore the possibilities of offering contract manufacturing to global vaccine developers so as to effectively utilise its existing manufacturing capacity. Aurobindo Pharma will actively seek customers in this space.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1379.25 -6.40 (-0.46%)
20-Apr-2026 10:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.30
Dr. Reddys Lab 1237.90
Cipla 1238.95
Zydus Lifesciences 941.85
Lupin 2332.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×